APO Research
Talk to an analyst

APO RESEARCH · REPORT

Humira

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.

Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.

In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.

Selected research

Market Outlook & Growth Opportunities

Global Humira Market Outlook and Growth Opportunities 2026

23 December 2025197 pages

Choose your research edition.

Industry ResearchHumira Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Humira Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Humira Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Humira Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Humira Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.

Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.

Read the full market overview

In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.

The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe is about 78%.

Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion is about 43%.

USA is the largest market, with a sales market share nearly 65%. Following USA, Europe is the second largest market with the sales market share of 30%.

Market competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.

This report provides an overview of the global Humira market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Humira and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Humira sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Humira market size, projected growth trends, production technologies, key applications, and end-use industries.

Humira Segment by Company

AbbVie

Eisai

Cadila Healthcare

Torrent Pharmaceuticals

Amgen

Boehringer Ingelheim

Humira Segment by Type

Humira Syringe

Humira Pen

Humira Segment by Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn’s Disease

Others

Humira Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Humira status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Humira market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Humira significant trends, drivers, influence factors in global and regions.

6. To analyze Humira competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Humira market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Humira and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Humira.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Humira market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Humira industry.

Chapter 3: Detailed analysis of Humira manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Humira in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Humira in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Humira Industry Trends Table 2. Humira Industry Drivers Table 3. Humira Industry Opportunities and Challenges Table 4. Humira Industry Restraints Table 5. Global Humira Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Humira Revenue Share by Company (2021-2026) Table 7. Global Humira Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Humira Sales Volume Share by Company (2021-2026) Table 9. Global Humira Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Humira Company Ranking, (2024-2026) & (USD Million) Table 11. Global Humira Key Company Manufacturing Base & Headquarters Table 12. Global Humira Company, Product Type & Application Table 13. Global Humira Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Humira by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Humira Syringe Table 18. Significant Companies of Humira Pen Table 19. Global Humira Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Humira Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Humira Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Humira Sales Volume Share by Type (2021-2026) Table 23. Global Humira Sales Volume Share by Type (2027-2032) Table 24. Global Humira Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Humira Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Humira Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Humira Sales Value Share by Type (2021-2026) Table 28. Global Humira Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Ankylosing Spondylitis Table 30. Significant Companies of Rheumatoid Arthritis Table 31. Significant Companies of Crohn’s Disease Table 32. Significant Companies of Others Table 33. Global Humira Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Humira Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Humira Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Humira Sales Volume Share by Application (2021-2026) Table 37. Global Humira Sales Volume Share by Application (2027-2032) Table 38. Global Humira Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Humira Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Humira Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Humira Sales Value Share by Application (2021-2026) Table 42. Global Humira Sales Value Share by Application (2027-2032) Table 43. Global Humira Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Humira Sales by Region (2021-2026) & (K Units) Table 45. Global Humira Sales Market Share by Region (2021-2026) Table 46. Global Humira Sales by Region (2027-2032) & (K Units) Table 47. Global Humira Sales Market Share by Region (2027-2032) Table 48. Global Humira Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Humira Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Humira Sales Value Share by Region (2021-2026) Table 51. Global Humira Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Humira Sales Value Share by Region (2027-2032) Table 53. Global Humira Market Average Price (USD/Unit) by Region (2021-2026) Table 54. Global Humira Market Average Price (USD/Unit) by Region (2027-2032) Table 55. Global Humira Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Humira Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Humira Sales by Country (2021-2026) & (K Units) Table 58. Global Humira Sales Market Share by Country (2021-2026) Table 59. Global Humira Sales by Country (2027-2032) & (K Units) Table 60. Global Humira Sales Market Share by Country (2027-2032) Table 61. Global Humira Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Humira Sales Value Market Share by Country (2021-2026) Table 63. Global Humira Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Humira Sales Value Market Share by Country (2027-2032) Table 65. AbbVie Company Information Table 66. AbbVie Business Overview Table 67. AbbVie Humira Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 68. AbbVie Humira Product Portfolio Table 69. AbbVie Recent Development Table 70. Eisai Company Information Table 71. Eisai Business Overview Table 72. Eisai Humira Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. Eisai Humira Product Portfolio Table 74. Eisai Recent Development Table 75. Cadila Healthcare Company Information Table 76. Cadila Healthcare Business Overview Table 77. Cadila Healthcare Humira Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. Cadila Healthcare Humira Product Portfolio Table 79. Cadila Healthcare Recent Development Table 80. Torrent Pharmaceuticals Company Information Table 81. Torrent Pharmaceuticals Business Overview Table 82. Torrent Pharmaceuticals Humira Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Torrent Pharmaceuticals Humira Product Portfolio Table 84. Torrent Pharmaceuticals Recent Development Table 85. Amgen Company Information Table 86. Amgen Business Overview Table 87. Amgen Humira Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Amgen Humira Product Portfolio Table 89. Amgen Recent Development Table 90. Boehringer Ingelheim Company Information Table 91. Boehringer Ingelheim Business Overview Table 92. Boehringer Ingelheim Humira Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Boehringer Ingelheim Humira Product Portfolio Table 94. Boehringer Ingelheim Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Humira Distributors List Table 98. Humira Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Humira Product Image Figure 2. Global Humira Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Humira Sales Value (2021-2032) & (US$ Million) Figure 4. Global Humira Sales (2021-2032) & (K Units) Figure 5. Global Humira Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Humira Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Humira Syringe Image Figure 10. Humira Pen Image Figure 11. Global Humira Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Humira Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Humira Sales Volume Share by Type (2021-2032) Figure 14. Global Humira Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Humira Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Humira Sales Value Share by Type (2021-2032) Figure 17. Ankylosing Spondylitis Image Figure 18. Rheumatoid Arthritis Image Figure 19. Crohn’s Disease Image Figure 20. Others Image Figure 21. Global Humira Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Humira Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Humira Sales Volume Share by Application (2021-2032) Figure 24. Global Humira Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Humira Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Humira Sales Value Share by Application (2021-2032) Figure 27. Global Humira Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Humira Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Humira Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Humira Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Humira Sales Value (2021-2032) & (US$ Million) Figure 32. North America Humira Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Humira Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Humira Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Humira Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Humira Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Humira Sales Value (2021-2032) & (US$ Million) Figure 38. South America Humira Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Humira Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Humira Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Humira Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Humira Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Humira Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Humira Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Humira Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Humira Syringe
  • Humira Pen
Applications
  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Others
Companies covered
  • AbbVie
  • Eisai
  • Cadila Healthcare
  • Torrent Pharmaceuticals
  • Amgen
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Humira Sales Value (2021-2032)
  4. 1.2.2 Global Humira Sales Volume (2021-2032)
  5. 1.2.3 Global Humira Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Humira Market Dynamics
  1. 2.1 Humira Industry Trends
  2. 2.2 Humira Industry Drivers
  3. 2.3 Humira Industry Opportunities and Challenges
  4. 2.4 Humira Industry Restraints
3 Humira Market by Company
  1. 3.1 Global Humira Company Revenue Ranking in 2025
  2. 3.2 Global Humira Revenue by Company (2021-2026)
  3. 3.3 Global Humira Sales Volume by Company (2021-2026)
  4. 3.4 Global Humira Average Price by Company (2021-2026)
  5. 3.5 Global Humira Company Ranking (2024-2026)
  6. 3.6 Global Humira Company Manufacturing Base and Headquarters
  7. 3.7 Global Humira Company Product Type and Application
  8. 3.8 Global Humira Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Humira Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Humira Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Humira Market by Type
  1. 4.1 Humira Type Introduction
  2. 4.1.1 Humira Syringe
  3. 4.1.2 Humira Pen
  4. 4.2 Global Humira Sales Volume by Type
  5. 4.2.1 Global Humira Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Humira Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Humira Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Humira Sales Value by Type
  9. 4.3.1 Global Humira Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Humira Sales Value by Type (2021-2032)
  11. 4.3.3 Global Humira Sales Value Share by Type (2021-2032)
5 Humira Market by Application
  1. 5.1 Humira Application Introduction
  2. 5.1.1 Ankylosing Spondylitis
  3. 5.1.2 Rheumatoid Arthritis
  4. 5.1.3 Crohn’s Disease
  5. 5.1.4 Others
  6. 5.2 Global Humira Sales Volume by Application
  7. 5.2.1 Global Humira Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Humira Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Humira Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Humira Sales Value by Application
  11. 5.3.1 Global Humira Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Humira Sales Value by Application (2021-2032)
  13. 5.3.3 Global Humira Sales Value Share by Application (2021-2032)
6 Humira Regional Sales and Value Analysis
  1. 6.1 Global Humira Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Humira Sales by Region (2021-2032)
  3. 6.2.1 Global Humira Sales by Region: 2021-2026
  4. 6.2.2 Global Humira Sales by Region (2027-2032)
  5. 6.3 Global Humira Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Humira Sales Value by Region (2021-2032)
  7. 6.4.1 Global Humira Sales Value by Region: 2021-2026
  8. 6.4.2 Global Humira Sales Value by Region (2027-2032)
  9. 6.5 Global Humira Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Humira Sales Value (2021-2032)
  12. 6.6.2 North America Humira Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Humira Sales Value (2021-2032)
  15. 6.7.2 Europe Humira Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Humira Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Humira Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Humira Sales Value (2021-2032)
  21. 6.9.2 South America Humira Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Humira Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Humira Sales Value Share by Country, 2025 VS 2032
7 Humira Country-level Sales and Value Analysis
  1. 7.1 Global Humira Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Humira Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Humira Sales by Country (2021-2032)
  4. 7.3.1 Global Humira Sales by Country (2021-2026)
  5. 7.3.2 Global Humira Sales by Country (2027-2032)
  6. 7.4 Global Humira Sales Value by Country (2021-2032)
  7. 7.4.1 Global Humira Sales Value by Country (2021-2026)
  8. 7.4.2 Global Humira Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Humira Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Humira Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Humira Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Humira Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Humira Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Humira Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Humira Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Humira Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Humira Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Humira Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Humira Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Humira Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Humira Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Humira Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Humira Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Humira Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Humira Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Humira Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Humira Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Humira Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Humira Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Humira Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Humira Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Humira Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Humira Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Humira Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Humira Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Humira Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Humira Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Humira Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Humira Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Humira Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Humira Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Humira Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Humira Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Humira Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Humira Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Humira Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Humira Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Humira Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Humira Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Humira Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Humira Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Humira Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Humira Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Humira Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Humira Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Humira Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Humira Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Humira Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Humira Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Humira Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Humira Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Humira Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Humira Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Humira Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Humira Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Humira Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Humira Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Humira Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Humira Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Humira Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Humira Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Humira Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Humira Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Humira Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Humira Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Humira Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Humira Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Humira Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Humira Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Humira Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Humira Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Humira Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Humira Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Humira Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Humira Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Humira Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Humira Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Humira Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Humira Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Humira Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Humira Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Humira Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Humira Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Humira Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Humira Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Humira Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Cadila Healthcare
  14. 8.3.1 Cadila Healthcare Company Information
  15. 8.3.2 Cadila Healthcare Business Overview
  16. 8.3.3 Cadila Healthcare Humira Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cadila Healthcare Humira Product Portfolio
  18. 8.3.5 Cadila Healthcare Recent Developments
  19. 8.4 Torrent Pharmaceuticals
  20. 8.4.1 Torrent Pharmaceuticals Company Information
  21. 8.4.2 Torrent Pharmaceuticals Business Overview
  22. 8.4.3 Torrent Pharmaceuticals Humira Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Torrent Pharmaceuticals Humira Product Portfolio
  24. 8.4.5 Torrent Pharmaceuticals Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Humira Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Humira Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Boehringer Ingelheim
  32. 8.6.1 Boehringer Ingelheim Company Information
  33. 8.6.2 Boehringer Ingelheim Business Overview
  34. 8.6.3 Boehringer Ingelheim Humira Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim Humira Product Portfolio
  36. 8.6.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Humira Value Chain Analysis
  2. 9.1.1 Humira Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Humira Sales Mode & Process
  6. 9.2 Humira Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Humira Distributors
  9. 9.2.3 Humira Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst